pharma news

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Patients struggling with NHS complexity, says report

For patients and GPs, accessing NHS services can feel like a "maze of dead ends and detours," according to a new poll.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Elderly man talks to younger female nurse beside a Grail screening vehicle

Grail's multi-cancer test fluffs its lines in UK trial

Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Head-to-head trial dents Novo Nordisk's obesity hopes

Patients struggling with NHS complexity, says report

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

Grail's multi-cancer test fluffs its lines in UK trial

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

pharma news

Editor's Picks